<p>中国苏轩堂药业（NASDAQ:SXTC - 获取免费报告）在周二交易前股价跳空下跌。该股票此前收于 6.4650 美元，但开盘价为 5.60 美元。中国苏轩堂药业的最后交易价格为 5.4010 美元，成交量为 69,414 股。</p>
<h2>分析师设定新的价格目标</h2>
<p>另外，Weiss Ratings 在 10 月 8 日星期三的一份报告中重申了对中国苏轩堂药业股票的 “卖出（e+）” 评级。一位分析师对该股票给予了卖出评级，根据 MarketBeat.com 的数据，中国苏轩堂药业目前的共识评级为 “卖出”。</p>
<p><strong>阅读我们关于 SXTC 的最新研究报告</strong></p>
<h2>中国苏轩堂药业股票表现</h2>
<p>该股票的 50 日移动平均价格为 1.02 美元，200 日移动平均价格为 1.36 美元。</p>
<p>中国苏轩堂药业（NASDAQ:SXTC - 获取免费报告）最近一次发布财报是在 12 月 31 日星期三。该公司报告本季度每股收益（EPS）为（4.50）美元。该季度的营业收入为 31 万美元。</p>
<h2>机构资金流入和流出</h2>
<p>一家机构投资者最近增加了在中国苏轩堂药业股票中的持仓。根据其最近向证券交易委员会提交的 13F 文件，Virtu Financial LLC 在第三季度将其在中国苏轩堂药业（NASDAQ:SXTC - 免费报告）的持仓增加了 107.5%。该公司在本季度额外收购了 15,013 股后，持有 28,983 股该公司的股票。根据其最近的 SEC 文件，Virtu Financial LLC 在中国苏轩堂药业的持股价值为 46,000 美元。机构投资者和对冲基金持有该公司 5.02% 的股票。</p>
<h2>中国苏轩堂药业公司简介</h2>
<p>（获取免费报告）</p>
<p>中国苏轩堂药业（NASDAQ:SXTC）是一家总部位于中国的生物制药公司，专注于基于肽的治疗药物的研究、开发、生产和商业化。该公司的产品线集中于针对肿瘤、内分泌和代谢疾病的新型治疗方案。通过利用专有的肽合成和制剂技术，中国苏轩堂旨在推进下一代生物制剂，以满足国内外市场未满足的医疗需求。</p>
<p>该公司的核心产品候选包括长效肽激素和肽药物偶联物，旨在提高患者的依从性和治疗效果。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票，胜过中国苏轩堂药业</li>
<li>黄金市场崩溃的那一天</li>
<li>忘掉人工智能，这将是下一个重大科技突破</li>
<li>~1.5 万亿美元的 SpaceX IPO：首次公开募股机会</li>
<li>警报：在明天市场开盘前抛售这五只股票！</li>
<li>黄金正在变得稀缺。</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在中国苏轩堂药业吗？</h2>
<p>在你考虑中国苏轩堂药业之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师以及他们推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而中国苏轩堂药业并不在名单上。</p>
<p>虽然中国苏轩堂药业目前在分析师中被评为卖出评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

美国制药 ETF - iShares

医疗业 ETF - SPDR

标普全球医疗股指数 ETF - iShares

中国苏轩堂药业

医疗业 ETF - Vanguard

<p>中国苏轩堂药业（NASDAQ:SXTC）股价在周二交易前从 $6.4650 跌至 $5.60，最终收于 $5.4010。分析师对该股票的共识评级为 “卖出”，Weiss Ratings 重申了 “卖出（e+）” 评级。该公司报告了每股亏损 ($4.50) 和上个季度的收入为 $0.31 百万。机构投资者 Virtu Financial LLC 增加了对该公司的持股比例，增幅为 107.5%。中国苏轩堂专注于用于肿瘤和代谢疾病的基于肽的治疗药物</p>

<p>China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC - Get Free Report) shares gapped down prior to trading on Tuesday . The stock had previously closed at $6.4650, but opened at $5.60. China SXT Pharmaceuticals shares last traded at $5.4010, with a volume of 69,414 shares traded.</p>
<div class="lb-trans"><p>中国苏轩堂药业（NASDAQ:SXTC - 获取免费报告）在周二交易前股价跳空下跌。该股票此前收于 6.4650 美元，但开盘价为 5.60 美元。中国苏轩堂药业的最后交易价格为 5.4010 美元，成交量为 69,414 股。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新的价格目标</h2>
</div><p>Separately, Weiss Ratings reiterated a &#34;sell (e+)&#34; rating on shares of China SXT Pharmaceuticals in a report on Wednesday, October 8th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, China SXT Pharmaceuticals presently has a consensus rating of &#34;Sell&#34;.</p>
<div class="lb-trans"><p>另外，Weiss Ratings 在 10 月 8 日星期三的一份报告中重申了对中国苏轩堂药业股票的 “卖出（e+）” 评级。一位分析师对该股票给予了卖出评级，根据 MarketBeat.com 的数据，中国苏轩堂药业目前的共识评级为 “卖出”。</p>
</div><p><strong>Read Our Latest Research Report on SXTC</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 SXTC 的最新研究报告</strong></p>
</div><h2>China SXT Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>中国苏轩堂药业股票表现</h2>
</div><p>The stock has a 50-day moving average price of $1.02 and a 200-day moving average price of $1.36.</p>
<div class="lb-trans"><p>该股票的 50 日移动平均价格为 1.02 美元，200 日移动平均价格为 1.36 美元。</p>
</div><p>China SXT Pharmaceuticals (NASDAQ:SXTC - Get Free Report) last posted its earnings results on Wednesday, December 31st. The company reported ($4.50) earnings per share (EPS) for the quarter. The business had revenue of $0.31 million during the quarter.</p>
<div class="lb-trans"><p>中国苏轩堂药业（NASDAQ:SXTC - 获取免费报告）最近一次发布财报是在 12 月 31 日星期三。该公司报告本季度每股收益（EPS）为（4.50）美元。该季度的营业收入为 31 万美元。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>An institutional investor recently raised its position in China SXT Pharmaceuticals stock. Virtu Financial LLC grew its position in China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC - Free Report) by 107.5% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 28,983 shares of the company's stock after acquiring an additional 15,013 shares during the quarter. Virtu Financial LLC's holdings in China SXT Pharmaceuticals were worth $46,000 as of its most recent SEC filing. Institutional investors and hedge funds own 5.02% of the company's stock.</p>
<div class="lb-trans"><p>一家机构投资者最近增加了在中国苏轩堂药业股票中的持仓。根据其最近向证券交易委员会提交的 13F 文件，Virtu Financial LLC 在第三季度将其在中国苏轩堂药业（NASDAQ:SXTC - 免费报告）的持仓增加了 107.5%。该公司在本季度额外收购了 15,013 股后，持有 28,983 股该公司的股票。根据其最近的 SEC 文件，Virtu Financial LLC 在中国苏轩堂药业的持股价值为 46,000 美元。机构投资者和对冲基金持有该公司 5.02% 的股票。</p>
</div><h2>China SXT Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>中国苏轩堂药业公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>China SXT Pharmaceuticals Inc NASDAQ: SXTC is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of peptide-based therapeutics. The company’s pipeline centers on novel treatments targeting oncology, endocrine and metabolic disorders. By leveraging proprietary peptide synthesis and formulation technologies, China SXT aims to advance next-generation biologics that address unmet medical needs in both domestic and international markets.</p>
<div class="lb-trans"><p>中国苏轩堂药业（NASDAQ:SXTC）是一家总部位于中国的生物制药公司，专注于基于肽的治疗药物的研究、开发、生产和商业化。该公司的产品线集中于针对肿瘤、内分泌和代谢疾病的新型治疗方案。通过利用专有的肽合成和制剂技术，中国苏轩堂旨在推进下一代生物制剂，以满足国内外市场未满足的医疗需求。</p>
</div><p>The company’s core product candidates include long-acting peptide hormones and peptide-drug conjugates designed to improve patient compliance and therapeutic efficacy.</p>
<div class="lb-trans"><p>该公司的核心产品候选包括长效肽激素和肽药物偶联物，旨在提高患者的依从性和治疗效果。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than China SXT Pharmaceuticals</li>
<li>The day the gold market broke</li>
<li>Forget AI, This Will Be the Next Big Tech Breakthrough</li>
<li>~$1.5T SpaceX IPO: Pre-IPO Opportunity</li>
<li>ALERT: Drop these 5 stocks before the market opens tomorrow!</li>
<li>Gold’s getting scarce.</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过中国苏轩堂药业</li>
<li>黄金市场崩溃的那一天</li>
<li>忘掉人工智能，这将是下一个重大科技突破</li>
<li>~1.5 万亿美元的 SpaceX IPO：首次公开募股机会</li>
<li>警报：在明天市场开盘前抛售这五只股票！</li>
<li>黄金正在变得稀缺。</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in China SXT Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在中国苏轩堂药业吗？</h2>
</div><p>Before you consider China SXT Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑中国苏轩堂药业之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and China SXT Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师以及他们推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而中国苏轩堂药业并不在名单上。</p>
</div><p>While China SXT Pharmaceuticals currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然中国苏轩堂药业目前在分析师中被评为卖出评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

中国苏轩堂药业（NASDAQ:SXTC）股价跳空下跌 - 以下是发生的情况